Early Development and Diabetes Applications Throughout the 1990s and early 2000s, pharmaceutical companies focused on creating injectable GLP-1 medications for type 2 diabetes management
Viral depletion of calcitonin receptors in the area postrema: a proof-of-concept study
Pharmacists, diabetes educators, nurse practitioners, and physicians will all need updated guidance regarding substitution protocols, biosimilar regulations, and insurance coverage changes
From study baseline to the end of follow-up, GLP-1RAs treatment resulted in statistically significant decreases in weight (MD = -2.32 kg, 95% CI: -4.21 to -0.43) and BMI (MD = -0.82 kg/m 2 , 95% CI: -1.47 to -0.17)
Foam or bubbles Some foaming during reconstitution is normal and resolves as the solution settles
pylori activity